Finetriax S (Ceftriaxone + sulbactam)
Combination therapy of ceftriaxone, sulbactam and disodium edetate for the management of multi-drug resistant septicemia
Use of rational combination therapies have been recommended by various studies in the past, for the treatment of multi-drug resistant (MDR) infections. An antibiotic adjuvant entity (AAE) of ceftriaxone, sulbactam and disodium edetate (Elores) was accepted for multi-drug resistant infections in India. The objective of the following retrospective study was to investigate the efficacy and safety of AAE in patients with sepsis due to extended spectrum beta lactamse (ESBL) and metallo-beta lactamase (MBL) producing pathogens.
The study was conducted in patients admitted in intensive care unit (ICU) at tertiary health care site in India, with enrollment from 24 March, 2012 to 7 Aug, 2012. Patients with bacterial septicemia aged between 12-65 years were enrolled for treatment with cephalosporins categories of antibiotics.